How effective is imatinib/Gleevec in treating leukemia?

The most important application of imatinib/Gleevec is in the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (CML). The cause of CML is the formation of the BCR-ABL fusion gene due to chromosomal translocation. This gene encodes an abnormally active tyrosine kinase that continuously sends signals for cell division and proliferation, promoting the generation and accumulation of leukemia cells in large numbers.

Imatinib can precisely bind to the ATP binding site of BCR-ABL kinase and inhibit its activity, thereby cutting off abnormal signaling, preventing further proliferation of leukemia cells, and gradually reducing their proportion in the blood and bone marrow. Clinical studies and long-term follow-up data show that most CML patients can achieve complete hematological remission, cytogenetic remission, or even deep molecular remission after using imatinib. This means that the patient's blood indicators, bone marrow morphology and molecular testing can all return to normal levels, and the survival period is significantly prolonged.

In addition, imatinib is also used in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), often in combination with chemotherapy or hematopoietic stem cell transplantation to improve remission and survival rates. Imatinib also exhibits unique targeted inhibitory effects in some cases of eosinophilia and other rare hematological diseases.

Its safety characteristics have been fully recognized in long-term use. Common side effects include mild to moderate edema, rash, muscle cramps, gastrointestinal discomfort, and mild bone marrow suppression, which are tolerated by most patients and can be relieved by dose adjustment or symptomatic treatment. A very small number of patients may experience liver function abnormalities or serious cardiac events, so it is recommended to regularly monitor blood, liver function and cardiac function during medication.

It can be said that the advent of imatinib not only completely changed the natural course of CML, but also created a new era of targeted therapy in hematological tumors. Its success has prompted the global development of more generations of BCR-ABL inhibitors to further optimize efficacy, overcome drug resistance, and bring more hope to patients.

Reference materials:https://www.gleevec.com/